Friday, November 14, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home AI & Quantum Computing

D-Wave Quantum Shares Plunge Following CEO’s Multi-Million Dollar Stock Disposal

Andreas Sommer by Andreas Sommer
November 14, 2025
in AI & Quantum Computing, Earnings, Insider Trading, Nasdaq, Tech & Software
0
D-Wave Quantum Stock
0
SHARES
12
VIEWS
Share on FacebookShare on Twitter

Investors in D-Wave Quantum witnessed a dramatic sell-off yesterday as the company’s stock price collapsed by more than 11%, closing the trading session at $23.36. This sharp decline was triggered by regulatory filings revealing that Chief Executive Officer Alan E. Baratz had disposed of a substantial portion of his holdings, a move that came just days after the quantum computing company reported impressive quarterly results.

CEO’s Transaction Raises Eyebrows

Documents filed with the SEC on Thursday detailed the significant transaction: on November 11, CEO Baratz liquidated 806,288 shares at an average price of $28.87 per share. The total value of this disposal reached $23.28 million, reducing the executive’s direct stake in the company by over 22%.

Market participants responded with immediate concern, initiating a wave of panic selling that drove the share price down from its previous level of $26.40 to an intraday low of $22.94. This represented a single-day decline of 11.5%, a substantial setback for a stock that had recently received positive analyst coverage.

Questionable Timing Following Strong Earnings

The timing of the CEO’s stock sale has generated considerable discussion among Wall Street observers. Mere days earlier, on November 6, D-Wave had released third-quarter financial results that significantly exceeded market expectations. The company reported revenue of $3.7 million, representing a doubling of sales compared to the same period last year, while its loss per share of $0.05 came in better than the projected $0.07 loss.

Should investors sell immediately? Or is it worth buying D-Wave Quantum?

This robust financial performance had prompted several analyst firms to issue bullish assessments:
– Benchmark increased its price target from $20 to $35
– Rosenblatt Securities raised its target to $40
– Both firms maintained their “buy” recommendations

The decision by the company’s chief executive to reduce his position so soon after these positive developments has left market participants questioning the motivation behind the transaction, potentially undermining investor confidence.

Additional Pressure from Warrant Expiration

Compounding the negative sentiment from the insider selling, D-Wave reminded investors about the approaching deadline for exercising public warrants. All outstanding warrants must be exercised by November 19, after which they will expire worthless. The final trading day for these instruments on the NYSE is expected to be November 17.

This corporate action may create additional downward pressure on the stock as warrant holders potentially liquidate positions to manage their exposure ahead of the expiration date.

Ad

D-Wave Quantum Stock: Buy or Sell?! New D-Wave Quantum Analysis from November 14 delivers the answer:

The latest D-Wave Quantum figures speak for themselves: Urgent action needed for D-Wave Quantum investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 14.

D-Wave Quantum: Buy or sell? Read more here...

Tags: D-Wave Quantum
Andreas Sommer

Andreas Sommer

About Andreas Sommer Over 40 years of expertise in market analysis, chart technical analysis, and strategic investment advisory. With more than four decades of experience in banking and financial journalism, Andreas Sommer is recognized as one of the leading analysts in the German-speaking market. His deep understanding of market dynamics and technical analysis has helped countless investors navigate complex financial markets.
Areas of Expertise:
  • Technical Chart Analysis
  • Strategic Investment Advisory
  • Market Trend Analysis
  • Financial Journalism
Andreas brings unparalleled insights from his extensive career in banking and financial markets, making him a trusted voice for investors seeking professional guidance.

Related Posts

Protara Therapeutics Stock
Analysis

Protara Therapeutics: A Biotech Stock at a Crossroads

November 14, 2025
Aclaris Therapeutics Stock
Analysis

Aclaris Therapeutics Stock Gains Momentum on Strong Clinical and Financial Updates

November 14, 2025
The Trade Desk Stock
Analysis

The Trade Desk’s Puzzling Market Disconnect

November 14, 2025
Next Post
MongoDB Stock

MongoDB Stock: New Leadership Fuels Growth Optimism

Realty Income Stock

Realty Income's Strategic Pivot: A Bold Leap Into Asset Management

Micron Stock

Micron Stock Soars as Memory Market Hits Unprecedented Highs

Recommended

Entertainment stock Trading

Analysts Express Optimism and High Price Targets for Netflix

2 years ago
Texas Instruments Stock

Texas Instruments: A Tale of Strong Dividends and Market Uncertainty

2 months ago
VanEck Video Gaming and eSports ETF Stock

Is the VanEck Gaming & eSports ETF Poised for Sustained Growth?

2 months ago
NetScout Stock

Mixed Signals for NetScout Investors

3 weeks ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin ASML BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Nike NIO Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Discovery Gold’s Stunning Financial Turnaround

Scilex Faces Pivotal Week with Dual Catalysts on the Horizon

Stagwell Stock: Igniting a Rally Through AI Innovation

Rocket Lab Stock Surges on NASA Mission Success and Record Earnings

Insider Sales at Globus Medical: Profit-Taking or Warning Signal?

Macerich Shares: Can Strong Fundamentals Overcome Market Pessimism?

Trending

Protara Therapeutics Stock
Analysis

Protara Therapeutics: A Biotech Stock at a Crossroads

by Dieter Jaworski
November 14, 2025
0

The recent quarterly report from Protara Therapeutics presents investors with a curious market puzzle. Despite posting financial...

Aclaris Therapeutics Stock

Aclaris Therapeutics Stock Gains Momentum on Strong Clinical and Financial Updates

November 14, 2025
The Trade Desk Stock

The Trade Desk’s Puzzling Market Disconnect

November 14, 2025
Discovery Gold Stock

Discovery Gold’s Stunning Financial Turnaround

November 14, 2025
Scilex Stock

Scilex Faces Pivotal Week with Dual Catalysts on the Horizon

November 14, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Protara Therapeutics: A Biotech Stock at a Crossroads
  • Aclaris Therapeutics Stock Gains Momentum on Strong Clinical and Financial Updates
  • The Trade Desk’s Puzzling Market Disconnect

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com